



Pfizer Inc.
275 North Field Drive
Lake Forest, IL 60045

April 27, 2018

**Pfizer Injectables Vitamin K1 Injection
(Phytonadione Injectable Emulsion, USP) Supply
Update Related to the Synthetic Cannabinoid
Outbreak**

Dear Valued Customer,

We are writing to inform you about an emerging public health situation related to synthetic cannabinoids that has caused an increase in demand of Vitamin K1 Injection (Phytonadione Injectable Emulsion, USP), and the steps Pfizer Injectables is taking to support physicians, pharmacists and patients.

Health officials have seen an increase in patients primarily in the Midwest believed to have inhaled synthetic cannabinoids laced with an anticoagulant that causes severe bleeding. Patients are being treated with high doses of Vitamin K1 Injection, and Pfizer Injectables is currently the sole provider. You can learn more about the situation and up-to-date details on the Illinois Department of Health website (<http://dph.illinois.gov/topics-services/prevention-wellness/medical-cannabis/synthetic-cannabinoids>).

In response to increased market demand, Pfizer Injectables has put the Vitamin K1 Injection in market reserve for all presentations. We have been monitoring the market situation closely and are increasing production to address the increased demand we have seen.

Pfizer Injectables Vitamin K1 Injection Offerings

| Unit of Sales NDC | Description |
|-------------------|--|
| 00409-9157-25 | Vitamin K1 Injection Neonate (phytonadione injectable emulsion, USP) 1 mg/0.5 mL Glass Ampul Novaplus® |
| 00409-9157-01 | Vitamin K1 Injection Neonate (phytonadione injectable emulsion, USP) 1 mg/0.5 mL Glass Ampul |
| 00409-9158-25 | Vitamin K1 Injection (phytonadione injectable emulsion, USP) 10 mg/mL Glass Ampul Novaplus® |
| 00409-9158-01 | Vitamin K1 Injection (phytonadione injectable emulsion, USP) 10 mg/mL Glass Ampul |

At this current time, we do not expect to stock out of Vitamin K1 Injection. However, we have placed product on market reserve/allocation so we can monitor ordering patterns in real-time. We will review and release orders daily for direct customer orders and trading partner orders. Orders will continue to release in full, and we will adjust this as demand requires.

Pfizer Injectables is committed to assisting during this period of increased demand, and ensuring you have the information you need to plan patient care. To check product availability and access the most up-to-date information please visit our website at https://www.pfizerinjectables.com/Injectables_Availability_Report. You can also contact our Supply Continuity Team at 1-844-646-4398 between 7:00 AM and 6:00 PM CT to discuss product availability (select option 1 [Customer], then option 3 [Supply Continuity Team]).

Best Regards,

Jodi Perez
Senior Director
Portfolio Team Lead, Drug Delivery Systems